Holen Sie sich die Stockscreener-App
4.74
1.25%
-0.06
Schlusskurs vom Vortag:
$4.80
Offen:
$4.85
24-Stunden-Volumen:
11,334
Relative Volume:
0.04
Marktkapitalisierung:
$154.67M
Einnahmen:
$1.95M
Nettoeinkommen (Verlust:
$-47.84M
KGV:
-3.1958
EPS:
-1.4832
Netto-Cashflow:
$-27.46M
1W Leistung:
+1.28%
1M Leistung:
-3.85%
6M Leistung:
-35.25%
1J Leistung:
+80.57%
1-Tages-Spanne:
$4.70
$4.88
1-Wochen-Bereich:
$4.605
$5.32
52-Wochen-Spanne:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.79 | 151.76M | 1.95M | -47.84M | -27.46M | -1.4832 |
TMO
Thermo Fisher Scientific Inc
|
587.14 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.89 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
589.63 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
319.63 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
144.71 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
IMDX|Insight Molecular Diagnostics Ord Shs|Price:4.700|Chg%:-0.040 - TradingKey
CareDx CEO On Precision Diagnostics Pivot, Oncology Expansion - insights.citeline.com
Insight Molecular Diagnostics Inc. Revenue Breakdown – LSE:0KCC - TradingView
Insight Molecular Diagnostics Ord Shs (IMDX) Institutional Confidence - TradingKey
Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMDX|Insight Molecular Diagnostics Ord Shs|Price:4.960|Chg%:-0.030 - TradingKey
Insight Molecular Diagnostics Inc. (IMDX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insight Molecular Diagnostics (IMDX) Showcases Promising Study o - GuruFocus
Medicare coverage confirmed for iMDx kidney-rejection monitoring test - Stock Titan
Enterprise value to revenue forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
MOLN Stock Price and Chart — NASDAQ:MOLN - TradingView
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - Sahm
IMDX Q1 2026 Earnings: Narrowing Losses and Cost Discipline Signal ProgressEstimate Accuracy - po-news-eg.net
Insight Molecular Diagnostics Inc. Announces Favorable Medicare Coverage Decision Supporting Commercial Adoption Of GraftAssure Assay Portfolio - marketscreener.com
Medicare expands coverage for transplant monito... - Pluang
iMDx Highlights Expanded Medicare Coverage for Donor-Derived Cell-Free DNA Transplant Testing - Quiver Quantitative
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - GlobeNewswire Inc.
Price to book forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Enterprise value to EBIT forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Price to sales forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME) - The Globe and Mail
Form 4 Insight Molecular Diagnostics Inc For: 6 July By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (Nasdaq: IMDX) details director RSU tax withholding - Stock Titan
Insight Molecular (IMDX) director uses 12,100 shares to cover RSU tax withholding - Stock Titan
If You Invested $1,000 in Insight Molecular Diagnostics Inc. (IMDX) - Stock Titan
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper - GlobeNewswire
Insight Molecular Diagnostics Inc. Actuals & Estimates (NASDAQ:IMDX) - TradingView
Insight Molecular Diagnostics Inc. Actuals & Estimates (BOATS:IMDX) - TradingView
IMDX Forecast — Price Target — Prediction for 2027 - TradingView
IMDX Q1 2026 Earnings: Narrower-than-expected loss drives stock surgeTrough Earnings Signal - dars.gov.et
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant - The Manila Times
Insight Molecular Diagnostics and ASTS Award Grant for Health Economics Study of In-House vs. Send-Out dd-cfDNA Testing in Kidney Transplantation - Quiver Quantitative
iMDx and ASTS fund $100,000 study on kidney transplant testing costs - Stock Titan
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Validates GraftAssure Assay Superiority - HarianBasis.co
Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment - Insider Monkey
12 High-Growth Micro-Cap Stocks to Buy Now - Insider Monkey
Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase - Stock Titan
IMDX Q1 2026 Earnings: EPS Surprises with 55% Beat Despite Negative ResultsEarnings Recovery Stocks - po-news-eg.net
Insight Molecular Diagnostics Inc. Announces Favorable Head-To-Head Data On Imdx's Graftassure With Competing NGS Assay Published In Clinical Chemistry - marketscreener.com
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry - The Manila Times
New lab test rivals DNA sequencing to monitor kidney transplants - Stock Titan
[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity - Stock Titan
Director Arno Andrew of Insight Molecular (IMDX) receives 32,331-share stock grant - Stock Titan
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Stock Price, News & Analysis - Kalkine
IMDX Q1 2026 Earnings: Narrowing Losses with 55% EPS Surprise Amid Revenue DisclosuresBuyback Announcement Report - newsline.com
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation - The Manila Times
Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring - Quiver Quantitative
IMDX GraftAssure Assay Sets New Standard in Screening - GlobeNewswire
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - The Manila Times
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insight Molecular Diagnostics Inc-Aktie (IMDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 27 '26 |
Buy |
3.64 |
250,923 |
913,134 |
12,684,884 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 24 '26 |
Buy |
3.53 |
38,880 |
137,083 |
12,433,961 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 16 '26 |
Buy |
3.45 |
102,057 |
351,658 |
12,033,896 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 20 '26 |
Buy |
3.88 |
40,690 |
157,967 |
12,114,700 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 17 '26 |
Buy |
3.57 |
40,114 |
143,251 |
12,074,010 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Feb 10 '26 |
Buy |
5.75 |
521,739 |
2,999,999 |
11,931,839 |
| James Andrea S. | Chief Financial Officer |
Oct 31 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
201,231 |
0.06%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):